Alzheimer’s drug results leave Lilly ‘excited’ but uncertain
The surprise positive effect shown by an experimental Alzheimer’s drug “excited” executives at Eli Lilly and Co., but it raised as many questions as it answered.
Health Care Businesses
Articles
Humane Society clinic to open with even bigger goal in mind
The Humane Society of Indianapolis is ready to open its new Animal Welfare Center in Haughville, featuring a low-cost vaccination clinic. The group wants to raise $750,000 to add a low-cost spay-and-neuter clinic to the center.
Lilly to book $790M Amylin payment in third quarter
Eli Lilly and Co. will book about $790 million in pretax income in the third quarter thanks to an early payment from former drug development partner Amylin Pharmaceuticals.
Lilly stock slips after competitors halt Alzheimer’s plans
Pfizer Inc., Johnson & Johnson and Elan Corp. are ending most plans to develop an Alzheimer’s drug after a second trial failure. Eli Lilly is developing a similar treatment.
Cautious hospitals trouble Hill-Rom
The investor drubbing sustained by Hill-Rom Holdings Inc. last week stemmed not so much from the new acquisition it announced as from the gloomy outlook in the North American hospital market.
Cook Medical shelves Midwest expansion plans
Cook Medical Inc. had been planning to open five new manufacturing plants over the next five years in small communities around the Midwest, including Indiana, but has shelved those plans because of the hit it will take from a new U.S. tax on medical devices.
Hill-Rom stock swoons after $400M acquisition
Investors reacted negatively Thursday after medical equipment and hospital bed maker Hill-Rom Holdings Inc. on Wednesday said it was acquiring Aspen Surgical Products for $400 million.
Potential Alzheimer’s drug fails first of four key trials
Bapineuzumab is in a race with a similar product from Indianapolis-based Eli Lilly and Co. to become the first therapy to target a cause for Alzheimer’s, rather than just its symptoms.
Survey: Solo practices nearly gone
Only 1 percent of the jobs given to Texas-based Merritt Hawkins over the past year were for solo practitioners, the physician recruiting firm reported this month. That’s down from 22 percent of all searches in 2004.
WellPoint agrees to pay for 3 children to get gene test
WellPoint Inc. said it will pay for DNA testing for three children to see if they have an inherited heart disease their father suffers from that often strikes without warning, reversing an earlier decision to deny coverage.
Potential Lilly antipsychotic falls short in study
Eli Lilly and Co. said a potential treatment for acute schizophrenia failed in a late-stage study that compared patients taking the drug to those taking a placebo.
Competing Alzheimer’s treatments facing long odds
Johnson & Johnson, Pfizer Inc. and Elan Corp are racing Indianapolis-based Eli Lilly and Co. to market the first broadly available drug designed to target a cause of Alzheimer’s, rather than just its symptoms. Analysts say the potential drugs are long shots.
Zoeller goes after closed Allcare Dental chain
A chain of dental offices that abruptly closed multiple Indiana locations in December 2010 left patients without care, refunds or records, according to a complaint filed by the Office of the Indiana Attorney General.
Lilly gets 6-month Cymbalta marketing extension
Eli Lilly and Co. said Friday that it has received an extra six months of marketing exclusivity on the antidepressant Cymbalta, its biggest selling drug. The extension could mean more than a billion dollars in sales for the Indianapolis drug maker.
Lilly cancer treatment fails trial in stomach cancer
Erbitux, a cancer treatment made by Indianapolis-based Eli Lilly and Co.'s Imclone unit, failed to help patients with advanced stomach tumors in a late-stage clinical trial.
Bristol-Myers to buy former Lilly partner Amylin for $5.3B
Bristol-Myers Squibb Co. has agreed to pay $5.3 billion to acquire former Eli Lilly and Co. partner Amylin Pharmaceuticals Inc., a maker of diabetes therapies. The deal is valued at about $7 billion, which includes Amylin’s debt and a payment to Eli Lilly and Co. of about $1.7 billion.
Covance plans $150M expansion, 465 jobs in Greenfield
The New Jersey-based pharmaceutical research company is seeking state and local incentives as part of the expansion, which would include a new laboratory, set to be finished in 2016. Covance already employs 565 workers at the site.
Analysis: How stocks will fare in ruling on health care law
The Supreme Court is expected to rule on the Affordable Care Act by the end of June. Here’s a roundup of how health care businesses would be affected under four different scenarios.
J&J, Bayer fail to win U.S. OK for expanded Xarelto use
If approved for acute coronary syndrome, Xarelto would compete with Effient from Indianapolis-based Eli Lilly and Co and Brilinta from London-based AstraZeneca Plc.
Medical startup plans 71 jobs, seeks incentives
The city of Indianapolis granted preliminary approval for an eight-year tax abatement to Arcamed Inc., which plans to purchase $1.4 million in equipment to design and manufacture titanium and case-tray systems for surgical instruments.